RSC Advances



View Article Online

View Journal | View Issue

PAPER

Check for updates

Cite this: RSC Adv., 2022, 12, 5386

Nano-[Fe₃O₄@SiO₂/*N*-propyl-1-(thiophen-2-yl) ethanimine][ZnCl₂] as a nano magnetite Schiff base complex and heterogeneous catalyst for the synthesis of pyrimido[4,5-*b*]quinolones⁺

Soheila Esmaili,^a Ahmad Reza Moosavi-Zare^{b*b} and Ardeshir Khazaei^{*a}

Nano-[Fe₃O₄@SiO₂/*N*-propyl-1-(thiophen-2-yl)ethanimine][ZnCl₂] as a nano magnetite Schiff base complex was designed and fully characterized by various analyses such as Fourier transform infrared spectroscopy (FT-IR), energy-dispersive X-ray spectroscopy (EDX), X-ray diffraction (XRD), thermal gravimetric analysis (TGA), differential thermal gravimetric analysis (DTA), vibrating sample magnetometry (VSM), scanning electron microscopy (SEM), and transmission electron micrographs (TEM). The presented nano magnetite Schiff base complex was used as a heterogeneous catalyst for the synthesis of pyrimido[4,5-*b*]quinolones by the reaction of aryl aldehyde, dimedone and 6-amino-1,3-dimethyluracil in EtOH : H_2O (7 : 3) as a solvent at 60 °C.

Received 11th January 2022 Accepted 4th February 2022

DOI: 10.1039/d2ra00213b

rsc.li/rsc-advances

1. Introduction

Heterocyclic compounds containing pyrimidine moieties in their structure show an important role in medicinal chemistry.1 Biological properties of pyrimido [4,5-b]quinolones give them special activities in medicinal chemistry such as antifungal,² anticancer,3 antimalarial,4 antiviral,5 anticancer,6 anti-inflammatory,7 antihistaminic,8 and anti-inflammatory activities.9 A significant method for the preparation of pyrimido[4,5-b]quinolones is the multi-component reaction of arvl aldehvde, dimedone and 6-amino-1,3-dimethyluracil.1 Multi-component reactions are one of the most successful methods in organic chemistry to increase the structural diversity and molecular complexity using a simple process without the formation of side-products and save energy, time, solvent and chemical materials and reduce the chemical waste.¹⁰⁻¹⁶ Multi-component reaction of aryl aldehyde, dimedone and 6-amino-1,3dimethyluracil is carried out by various catalysts including nano-[Fe₃O₄@-SiO₂@R-NHMe₂][H₂PO₄],¹ SBA-15/PrN(CH₂PO₃-H₂)₂,¹⁷ [TSSECM],¹⁸ Fe₃O₄@cellulose sulfuric acid,¹⁹ Agarentrapped sulfonated DABCO,²⁰ [C₄(DABCO)₂]·2OH,²¹ nanocrystalline MgO,²² [H₂-DABCO][ClO₄]₂ (ref. 23) and [bmim]Br.²⁴ Due to the importance of pyrimido [4,5-*b*] quinolones in medicinal chemistry, finding new methods for the preparation of them is still required.

Heterogeneous catalysts are a group of catalysts in which the starting materials and the catalyst are not in the same phase. Increasing the active surface of the catalyst to create a suitable substrate for the reaction and also the stability of this substrate, which causes its reusability of the catalyst, is one of their special advantages.²⁵

Adsorption of starting materials on the surface of the catalyst, reaction and desorption of chemical products is done on the active surface of the heterogeneous catalyst. Faster production of large-scale products, selective products formation and recovery of this group of catalysts are features that have made them significant in the chemical industry.²⁶

The placement of these catalysts on a magnetic iron oxide surface, due to its stability, ease of preparation and cheapness of it, gives them some capabilities, including the simple separation of the catalyst from the reaction mixture by an external magnet without filtration.²⁷⁻³³

The zinc(π) ions are important factors for many biological processes, their complexes being present in a wide range of biological processes. Also, Zn complexes containing thiophene moieties show antimycobacterial properties. These complexes show higher biological activities than free metal ion.^{34–36} Having above facts, in continues to previous works on the design and use heterogeneous catalyst based on Schiff base complex in organic synthesis,^{37–43} we have introduced a new nano magnetite Schiff base complex namely, nano-[Fe₃O₄@SiO₂/*N*-propyl-1-(thiophen-2-yl)ethanimine][ZnCl₂] and used it as an efficient heterogeneous catalyst for the preparation of pyrimido[4,5-*b*] quinolones by the reaction of aryl aldehyde, dimedone and 6-amino-1,3-dimethyluracil (Scheme 1).

[&]quot;Department of Organic Chemistry, Faculty of Chemistry, Bu-Ali Sina University, Hamedan, 6517838683, Iran. E-mail: Khzaei_1326@yahoo.com.

^bDepartment of Chemical Engineering, Hamedan University of Technology, Hamedan, 65155, Iran. E-mail: moosavizare@yahoo.com.

[†] Electronic supplementary information (ESI) available. See DOI: 10.1039/d2ra00213b



2. Results and discussion

2.1. Synthesis and characterization of catalyst

Zinc(π) Schiff base complexes in tetrahedral form with coordination of a Schiff base ligand containing thiophene ring and salicylaldehyde derivatives are previously reported.^{36,44} With this issue in mind, we have decided to design a new nano magnetite Schiff base complex of zinc(π) which coordinated with a ligand containing thiophene moieties.

For this purpose, to design and preparation of the nano magnetite Schiff base complex, initially by the reaction of (3-aminopropyl)triethoxysilane with 2-acetyl thiophen the Schiff base ligand was prepared. $ZnCl_2$ was added to prepared ligand and stirred in dry toluene to give $(OEt)_3Si/N$ -propyl-1-(thiophen-2-yl)ethanimine as a Schiff base complex. In the next step, $Fe_3O_4(@SiO_2 \text{ nanoparticles were prepared according to previous literature^{30,31} and dispersed in toluene and then reacted with Schiff base complex to give nano-<math>[Fe_3O_4(@SiO_2/N)-propyl-1-(thiophen-2-yl)]$ ethanimine][ZnCl₂] as a nano magnetite Schiff base complex (Scheme 2). The presented nano particles were fully



Scheme 2 The preparation of nano-[Fe $_3O_4$ @SiO $_2/N$ -propyl-1-(thio-phen-2-yl)ethanimine][ZnCl $_2$].



Fig. 1 The FT-IR spectrum of nano magnetite Schiff base complex in comparison with other species in its structure.

characterized by various analyses including FT-IR, EDX, SEM mapping, FESEM, TEM, TGA, DTG and VSM analyses.

FT-IR spectrum of nano-[Fe₃O₄@SiO₂/*N*-propyl-1-(thiophen-2-yl)ethanimine][ZnCl₂] was studied. According that, the peaks which observed at 1104 cm⁻¹ and 790 cm⁻¹ could be related to the un-symmetric and symmetric linear stretching vibrations of Si–O–Si bonding respectively.⁴⁵ Also, another peak at 1604 cm⁻¹ could be corresponded to stretching mode of C=N bond in nano-[Fe₃O₄@SiO₂/*N*-propyl-1-(thiophen-2-yl)ethanimine] [ZnCl₂] which coordinated with zinc chloride (Fig. 1).

To show the presence of the expected elements in nano magnetite Schiff base complex, energy-dispersive X-ray spectroscopy (EDX) from nano- $[Fe_3O_4@SiO_2/N$ -propyl-1-(thiophen-2-yl)ethanimine][ZnCl₂] was studied and the desired elements including carbon, oxygen, nitrogen, sulfur, iron, silicon, zinc and chlorine were presented in the structure of nano magnetite Schiff base complex (Fig. 2).

In another study, to show the expected elements in the catalyst, the SEM analysis was coupled with EDX analysis (SEM mapping) to determine carbon, oxygen, nitrogen, sulfur, iron,



Fig. 2 The EDX analysis of nano magnetite Schiff base complex.



Fig. 3 SEM coupled EDX (SEM mapping) of nano magnetite Schiff base complex.

silicon, zinc and chlorine in the structure of nano magnetite Schiff base complex (Fig. 3).

The morphology size of the prepared nano magnetite Schiff base complex were studied by the scanning electron microscope (SEM) micrographs of nano- $[Fe_3O_4@SiO_2/N-propyl-1-(thiophen-$



Fig. 4 The FESEM analysis of nano magnetite Schiff base complex.



Fig. 5 TEM image of nano magnetite Schiff base complex.







Fig. 7 Vibrating sample magnetometer (VSM) analysis of nano magnetite Schiff base complex.

Paper

Entry	Solvent	Catalyst amount (mg)	Temp. (°C)	Time (min)	Yield ^a (%)
1	EtOH : $H_2O(7:3)$	10	60	20	86
2	EtOH : $H_2O(7:3)$	20	60	20	93
3	EtOH : $H_2O(7:3)$	30	60	20	92
4	EtOH : $H_2O(7:3)$	40	60	20	90
5	EtOH : $H_2O(7:3)$	20	r.t.	270	65
6	EtOH : $H_2O(7:3)$	20	Reflux	20	90
7	H ₂ O	20	Reflux	30	80
8	Ethyl acetate	20	Reflux	30	40
9	CHCl ₃	20	Reflux	30	24
10	CH_2Cl_2	20	Reflux	30	Trace
11	<i>n</i> -Hexane	20	Reflux	30	Trace
12	CH ₃ CN	20	Reflux	360	16
13	EtOH	20	Reflux	20	85
14	_	20	60	60	Trace
15	EtOH : $H_2O(7:3)$	_	Reflux	360	Trace

 Table 1
 The effect of the catalyst amount, kinds of solvent and temperature on the reaction of benzaldehyde (1 mmol), 6-amino-1,3-dime-thyluracil (1 mmol) and dimedone (1 mmol) in the presence of nano magnetite catalyst

2-yl)ethanimine][ZnCl₂]. According this analysis, indicates that the particles were prepared in nano size, less than 100 nanometers (Fig. 4).

propyl-1-(thiophen-2-yl)ethanimine][ZnCl₂], were studied by transmission electron microscopy (TEM). As it is shown in Fig. 5, indicates that, some particles of the catalyst were prepared in nano size (Fig. 5).

For further studies on the size of prepared nano particles of the catalyst, the presented particles of nano- $[Fe_3O_4@SiO_2/N-$

Table 2 Synthesis of pyrimido[4,5-b]quinolones using nano magnetite catalyst

Entry	Product	Time (min)	Yield ^{a} (%)	Mp $^{\circ}$ C (Lit.) ^{ref}
1		20	93	282–284 (280–285) ¹⁷
2		20	95	232–234 (232–236) ¹⁹
3		20	94	295–297 (296–297) ¹
4		20	95	323-326 (>300) ¹

Entry	Product	Time (min)	Yield ^{a} (%)	Mp $^{\circ}$ C (Lit.) ^{ref}
5		20	94	236–239 (234) ¹⁹
6		20	87	288–290 (279–280) ¹
7	OMe MeO O O O O O O O O O O O O O O O O	20	62	238–240 (—)
8		20	68	305 (>300) ¹⁹
9		20	92	328-330 (—)
10	Br O O O N N N O H	20	74	280–280 $(285–287)^1$
11		20	50	299–303 (>300) ¹⁷
12		20	45	251–254 (253–255) ¹

^{*a*} Isolated yield.

Paper

To show the thermal stability of nano magnetite catalyst in organic reactions, thermal gravimetric analysis (TGA) of nano-[Fe₃O₄@SiO₂/*N*-propyl-1-(thiophen-2-yl)ethanimine][ZnCl₂] was studied. According that, the prepared catalyst could be used until 220 °C without any special changes in its chemical structure (Fig. 6). By the increasing the temperature more than 220 °C, the organic part of the catalyst namely Schiff base ligand will be decomposed. Weight loss at this temperature may be due to the organic part leaving the catalyst structure.

The magnetic behavior of nano magnetite catalyst was measured using vibrating sample magnetometer (VSM) at room temperature. The saturation magnetizations for nano-[Fe₃- O_4 @SiO₂/*N*-propyl-1-(thiophen-2-yl)ethanimine][ZnCl₂] was found to be 22 emu g⁻¹. The related hysteresis loop of the nano magnetite catalyst is depicted in Fig. 7.

2.2. Catalytic properties of the catalyst

After the preparation and identification of nano- $[Fe_3O_4@SiO_2/N$ -propyl-1-(thiophen-2-yl)ethanimine][ZnCl₂] as a nano magnetite Schiff base complex, the catalytic application of it was tested on the synthesis of pyrimido[4,5-*b*]quinolones. For this purpose, the reaction of benzaldehyde, 6-amino-1,3-dimethyluracil and dimedone was considered as a model



Scheme 3 The proposed mechanism for the synthesis of pyrimido [4,5-*b*]quinolones.



Fig. 8 The reusability of the catalyst. The reactions were carried out for the synthesis of compound (1) in EtOH : H_2O (7 : 3) using 0.02 g of catalyst within 20 minutes at 60 °C.

reaction and the effect of the catalyst amounts, temperature and various solvents were examined on this reaction. The results were depicted in Table 1. According that, the best result was obtained using 20 mg of nano magnetite catalyst in EtOH : H_2O (7 : 3) as a solvent at 60 °C. various solvent including ethyl acetate, *n*-hexane, CH₂Cl₂, CHCl₃, CH₃CN and H₂O, which using in this reaction, did not improve the yields and reaction times of products. Also, the solvent-free and catalyst-free conditions were tested on the model reaction which there was no significant progress (Table 1).

2.3. Efficiency of the catalyst

After finding the best reaction condition, to show the efficiency of the catalyst, for the preparation of pyrimido[4,5-*b*]quinolones using nano magnetite catalyst, various aromatic aldehydes containing electron withdrawing substituents, electronreleasing substituents and halogens, were examined in this reaction to demonstrate the generality and capability of the catalyst (Table 2). As it is depicted in Table 2, indicates that the



Fig. 9 The IR spectrum of fresh catalyst in comparison with reused catalyst.

Table 3	Comparison of the result	ts of the reaction of 4-c	hlorobenzaldehyde,	dimedone and	6-amino-1,3-dimethyluracil	catalyzed by nano
magnetit	e catalyst with some previ	viously reported catalysts				

Catalyst & temperature	Catalyst amount	Time (min)	Yield ^a (%)	Ref.
P-TSA, PEG : H_2O (v/v = 1 : 1), 80 °C	20 mol%	240	78	46
Fe ₃ O ₄ @cellulose-SO ₃ H, H ₂ O, 80 °C	25 mg	20	90	19
[bmim]Br, H ₂ O, 95 °C	2 mL	210	90	24
[TSSECM], 125 °C	24 mg	40	92	18
SBA-15/PrN(CH ₂ PO ₃ H ₂) ₂ , 100 $^{\circ}$ C	10 mg	15	85	17
Nano magnetite catalyst, 60 °C	20 mg	20	94	b
^{<i>a</i>} Isolated vield. ^{<i>b</i>} Our work.				

presented catalyst successfully carried out the reaction with high yields and suitable reaction times.

In a proposed mechanism which is supported by the literature,^{17-24,44} in the first step, dimedone in enole form was reacted with activated aldehyde by the catalyst to give (I) and then by removing of one molecule of H2O, intermediate (II) as an Michael acceptor was prepared. In the next step, by the reaction of 6-amino-1,3-dimethyluracil with (II), which was activated by the catalyst, (III) was obtained. Finally, by the intramolecular nucleophilic attack in intermediate (III), the desired product was prepared after removing of one molecule of H2O and tautomerization (Scheme 3).

2.4. The recovery of the catalyst

To examine the reusability of nano magnetite catalyst, the reaction of benzaldehyde, 6-amino-1,3-dimethyluracil and dimedone as a model reaction was tested in the presence of reused catalyst, which the time and yield of the reactions are acceptable for two runs (Fig. 8). The IR spectrum of fresh catalyst and reused catalyst was compared with each other to confirm the stability of catalyst after reusing it for two runs (Fig. 9).

To show the applicability and the efficiency of nano magnetite catalyst with some previous reported catalysts for the preparation of pyrimido [4,5-b] quinolones, we have summarised the results of these catalysts for the reaction of 4-chlorobenzaldehyde, dimedone and 6-amino-1,3-dimethyluracil in Table 3. As it is shown in Table 3, indicates that the presented nano magnetite catalyst is superior from the some reported catalyst to catalyze the reaction.

3. Conclusions

Nano-[Fe₃O₄@SiO₂/N-propyl-1-(thiophen-2-yl)ethanimine]

[ZnCl₂] as a nano magnetite Schiff base complex was prepared and fully characterized by various analyses and successfully used as a heterogeneous catalyst for the synthesis of pyrimido [4,5-b]quinolones by the reaction of aryl aldehyde, dimedone and 6-amino-1,3-dimethyluracil in EtOH: H_2O (7:3) as a solvent at 60 °C. The generality, high yields, short reaction times, clean reaction condition, simplicity and ease of separation of the catalyst from the reaction mixture are some important advantages of the presented methodology.

Experimental 4.

4.1. Materials

All chemicals were purchased from the chemical companies Merck or Fluka. The known products were identified by comparison of their melting points and spectral data with those reported in the literature.

4.2. General procedure for synthesis of Fe_3O_4

To a mixture of distilled water (25 mL) and hydrochloric acid 37% (0.85 mL) was added FeCl₃·6H₂O (10 mmol) and FeCl₂-·4H₂O (19.33 mmol) and stirred in an oil bath at 60 °C under nitrogen atmosphere for 30 minutes. This solution was added drop wise to a solution of NaOH (1.5 M, 250 mL) in an oil bath at 60 °C for 2 hours. The prepared mixture was vigorously stirred for 30 minutes. Lastly, the iron oxide nanoparticles were separated with an external magnet and washed twice with distilled water.30

4.3. General procedure for synthesis of Fe_3O_4 (a)SiO₂ coreshell

 Fe_3O_4 nanoparticles (3 g) were dispersed in a mixture of ethanol and water (200:10, % v/v) using an ultrasonic bath for 10 minutes. Then 10 mL of ammonia solution (25%) and tetramethylorthosilicate (3 mL) were added dropwise to the mixture and stirred at room temperature for 24 hours. The obtained Fe₃O₄(a)SiO₂ nanoparticles were separated by an external magnet, washed with methanol and finally dried in an oven.30,31

4.4. Synthesis of (OEt)₃Si/N-propyl-1-(thiophen-2-yl) ethanimine

In a round-bottomed flask connected to a reflux condenser (3aminopropyl)triethoxysilane (1 mmol) and 2-acetyl thiophen (1 mmol) were added and stirred at 90 °C for 24 hours under solvent free condition. Finally, the obtained product as a Schiff base ligand was purified by washing with dry CH₂Cl₂. The product was identified by FT-IR and ¹H NMR.

4.5. Metalation of (OEt)₃Si/N-propyl-1-(thiophen-2-yl) ethanimine

In a round-bottomed flask, the prepared ligand (2 mmol) and ZnCl₂ (1 mmol) were added and stirred in dry toluene (10 mL) under reflux condition for 24 hours. After the complexation

Paper

process was completed, the prepared Schiff base complex was filtered off and washed with ethanol.

4.6. Synthesis of nano-[Fe $_3O_4$ @SiO $_2/N$ -propyl-1-(thiophen-2-yl)ethanimine][ZnCl $_2$]

 Fe_3O_4 @SiO₂ nanoparticles (2 g) were dispersed in toluene (10 mL) for 10 minutes. Then, the prepared Schiff base complex (1 mmol) was added to the mixture and stirred for 24 hours under reflux condition. Finally, nano magnetite Schiff base complex was obtained and separated by an external magnet, washed with ethanol (three times) and dried at 60 °C.

4.7. General procedure for synthesis of pyrimido[4,5-*b*] quinolones

In a round-bottomed flask which connected to a reflux condenser, a mixture of compounds containing of aromatic aldehydes (1 mmol), 6-amino-1,3-dimethyluracil (1 mmol, 0.155 g), dimedone (1 mmol, 0.140 g) and nano magnetite Schiff base complex (0.02 g) as a catalyst were stirred in ethanol: H_2O (7 : 3) (3 mL) as a solvent at 60 °C. After the completion of the reaction as monitored by TLC (*n*-hexane/ethyl acetate: 1/2), the reaction mixture was extracted by ethanol and the magnetite catalyst was separated by an external magnet and washed with acetone for three times to reuse for the next run. The desired product was purified by the recrystallization in ethanol (70%).

4.8. Selected spectral data

1,3,8,8-Tetramethyl-5-phenyl-7,8,9,10-tetrahydropyrimido [**4,5-***b*]quinoline-2,4,6(1*H*,3*H*,5*H*)-trione (1). IR (KBr, cm⁻¹): 3363, 3203, 2955, 2932, 1700, 1655, 1614, 1507, 1363, 1257; ¹H NMR (300 MHz, DMSO-*d*₆): δ 1.06 (s, 3H), 1.15 (s, 3H), 2.31 (s, 2H), 2.41 (s, 2H), 3.12 (s, 3H), 3.38 (s, 3H), 5.5 (s, 1H), 7.12 (d, *J* = 6.00 Hz, 2H), 7.23 (d, *J* = 6.00 Hz, 2H), 7.32 (s, 1H), 12.84 (s, 1H); ¹³C-NMR (DMSO-*d*₆, 300 MHz): δ 27.5, 28.4, 29.3, 30.8, 31.6, 33.4, 44.0, 49.9, 88.3, 114.2, 125.7, 126.8, 128.4, 140.2, 150.6, 155.1, 16.1, 176.5, 199.8.

5-(4-Fluorophenyl)-1,3,8,8-tetramethyl-5,8,9,10-tetrahydropyrimido[4,5-*b*]quinoline-2,4,6(1*H*,3*H*,7*H*)-trione (2). IR (KBr, cm⁻¹): 3361, 3258, 3217, 2963, 2934, 3895, 1692, 1655, 1593, 1505, 1219, 1157, 761, 507; ¹H NMR (300 MHz, DMSO-*d*₆): δ 1.05 (s, 3H), 1.13 (s, 3H), 2.31 (s, 2H), 2.41 (s, 2H), 3.12 (s, 3H), 3.38 (s, 3H), 5.47 (s, 1H), 7.06–7.12 (m, 3H) (7.33 s, 1H), 12.85 (s, 1H) ¹³C-NMR (DMSO-*d*₆, 300 MHz): δ 27.5, 28.5, 29.3, 30.8, 31.6, 32.9, 44.0, 49.9, 88.2, 114.2, 115.1, 128.5, 136.1, 150.6, 155.1, 159.1, 162.3, 164.1, 176.5, 199.8.

5-(4-Chlorophenyl)-1,3,8,8-tetramethyl-5,8,9,10-tetrahydropyrimido[4,5-*b*]quinoline-2,4,6(1*H*,3*H*,7*H*)-trione (3). IR (KBr, cm⁻¹): 3405, 3363, 3226, 2961, 2941, 2885, 1696, 1655, 1595, 152, 1509, 1362, 1257, 1014, 925, 784, 500; ¹H NMR (300 MHz, DMSO-*d*₆): δ 1.05 (s, 3H), 1.13 (s, 3H), 2.29 (s, 2H), 2.39 (s, 2H), 3.12 (s, 3H), 3.37 (s, 3H), 5.39 (s, 1H), 6.63 (d, *J* = 6.00 Hz, 2H), 6.88 (d, *J* = 6.00 Hz, 2H), 7.29 (s, 1H), 12.84 (s, 1H); ¹³C-NMR (DMSO-*d*₆, 300 MHz): δ 27.5, 28.4, 29.3, 30.7, 31.5, 32.6, 44.0, 50.0, 88.6, 114.5, 115.2, 127.7, 129.9, 150.6, 154.9, 155.3, 164.0, 176.4, 199.8. 5-(2,4-Dichlorophenyl)-1,3,8,8-tetramethyl-5,8,9,10-tetrahydropyrimido[4,5-*b*]quinoline-2,4,6(1*H*,3*H*,7*H*)-trione (4). IR (KBr, cm⁻¹): 3280, 3221, 3093, 2957, 2931, 2875, 1704, 1661, 1643, 1494, 1379, 1211, 1149, 1046, 962, 845, 755; ¹H NMR (300 MHz, DMSO- d_6): δ 0.90 (s, 3H), 1.05 (s, 3H), 1.98 (d, J = 15.0 Hz, 1H), 2.21 (d, J = 15.0 Hz, 1H), 2.57 (s, 2H), 3.06 (s, 3H), 3.46 (s, 3H), 5.14 (s, 1H), 7.28–7.35 (m, 3H), 9.05 (s, 1H); ¹³C-NMR (DMSO- d_6 , 300 MHz): δ 26.7, 28.0, 29.6, 30.7, 32.4, 34.0, 50.4, 89.6, 110.8, 126.9, 128.7, 131.3, 133.6, 134.0, 143.0, 144.6, 150.5, 150.9, 160.9, 194.8.

5-(4-Nitorophenyl)-1,3,8,8-tetramethyl-5,8,9,10-tetrahydropyrimido[4,5-*b*]quinoline-2,4,6(1*H*,3*H*,7*H*)-trion (5). IR (KBr, cm⁻¹): 3367, 3337, 3203, 2961, 2911, 1697, 1671, 1592, 1512, 1412, 1344, 1253, 1045, 748, 583; ¹H NMR (300 MHz, DMSO- d_6): δ 1.06 (s, 3H), 1.14 (s, 3H), 2.33 (s, 2H), 2.43 (2H), 3.12 (s, 3H), 3.38 (s, 3H), 5.60 (s, 1H), 7.35–7.40 (m, 2H), 8.12 (d, *J* = 9, 2H), 12.77 (s, 1H); ¹³C-NMR (DMSO- d_6 , 300 MHz): δ 27.7, 28.5, 29.2, 30.8, 31.6, 34.1, 43.9, 49.9, 87.6, 113.8, 123.6, 128.2, 145.9, 149.5, 150.6, 155.1, 164.1, 176.7, 199.7.

5-(3,4,5-Trimethoxyphenyl)-1,3,8,8-tetramethyl-5,8,9,10-tetrahydropyrimido[4,5-*b*]quinoline-2,4,6(1*H*,3*H*,7*H*)-trione (7). IR (KBr, cm⁻¹): 3421, 3191, 2997, 2944, 2875, 2839, 1703, 1656, 1600, 15.6, 1467, 1415, 1358, 1257, 1125, 998, 853, 786, 518, 490; ¹H NMR (300 MHz, DMSO-*d*₆): δ 1.07 (s, 3H), 1.16 (s, 3H), 2.31 (d, *J* = 6.0 Hz, 2H), 2.41 (d, *J* = 15.0 Hz, 2H), 3.15 (s, 3H), 3.65 (s, 3H), 3.67 (s, 9H), 5.45 (s, 1H), 6.39 (s, 1H), 7.30(s, 1H), 12.91 (s, 1H); ¹³C-NMR (DMSO-*d*₆, 300 MHz): δ 27.0, 28.5, 29.5, 30.8, 31.4, 33.5, 44.0, 49.9, 56.2, 60.4, 88.0, 104.4, 114.5, 135.7, 135.8, 150.6, 152.9, 155.0, 164.2, 176.7, 199.7.

5-(4-Hydroxy-3-methoxyphenyl)-1,3,8,8-tetramethyl-5,8,9,10tetrahydropyrimido[4,5-*b*]quinoline-2,4,6(1*H*,3*H*,7*H*)-trione (9). IR (KBr, cm⁻¹): 3426, 3302, 3225, 3080, 2961, 1703, 1661, 1644, 1615, 1379, 1359, 1208, 1126, 1034; ¹H NMR (300 MHz, DMSO d_6): δ 0.94 (s, 3H), 1.06 (s, 3H), 2.06 (d, *J* = 15.0 Hz, 1H), 2.24 (d, *J* = 18.0 Hz, 1H), 2.58 (d, *J* = 9.0 Hz, 2H), 3.13 (s, 3H), 3.46 (s, 3H), 3.71 (s, 3H), 4.81 (s, 1H), 6.59–6.6 (s, 2H), 6.81 (s, 1H), 8.67 (s, 1H), 8.99 (s, 1H); ¹³C-NMR (DMSO- d_6 , 300 MHz): δ 26.8, 28.1, 29.7, 30.6, 32.5, 33.4, 39.9, 50.5, 55.9, 91.0, 112.4, 112.7, 115.3, 120.17, 138.1, 143.9, 145.2, 147.2, 149.7, 151.0, 161.2, 195.1.

5-(3-Bromophenyl)-1,3,8,8-tetramethyl-5,8,9,10-tetrahydropyrimido[4,5-*b*]quinoline-2,4,6(1*H*,3*H*,7*H*)-trione (10). IR (KBr, cm⁻¹): 3410, 3163, 2961, 2933, 2872, 1697, 1593, 1507, 1355, 1303, 1244, 1204, 1145, 936, 778; ¹H NMR (300 MHz, DMSO-*d*₆): δ 1.06 (s, 3H), 1.13 (s, 3H), 2.31 (s, 2H), 2.42 (s, 2H), 3.13 (s, 3H), 3.37 (s, 3H), 5.51 (s, 1H), 7.13 (d, *J* = 6.0 Hz, 1H), 7.22 (t, *J* = 6 Hz, 1H), 7.27 (s, 1H), 7.32 (d, *J* = 6 Hz, 1H), 12.85 (s, 1H); ¹³C NMR (300 MHz, DMSO-*d*₆): δ 27.4, 28.5, 29.3, 30.8, 31.6, 33.3, 43.9, 49.9, 87.7, 113.8, 122.0, 126.0, 128.7, 129.6, 130.5, 143.5, 150.6, 155.2, 164.1, 176.6, 199.7.

Conflicts of interest

There are no conflicts to declare.

Acknowledgements

We thank the Bu-Ali Sina University, Hamedan University of Technology for financial support to our research group.

Notes and references

- 1 A. Zare, N. Lotfifar and M. Dianat, *J. Mol. Struct.*, 2020, **1211**, 128030.
- 2 A. Drabczynska, C. E. Muller, A. Schiedel, B. Schumacher,
 J. K. Wojciechowska, A. Fruzinski, W. Zobnina,
 O. Yuzlenko and K. Kiec-Kononowicz, *Bioorg. Med. Chem.*,
- 2007, 15, 6956–6974.
 J. A. Valderrama, P. Colonelli, D. Vasquez, M. F. Gonzalez,
- J. A. Rodríguez and C. Theoduloz, *Bioorg. Med. Chem.*, 2008, 16, 10172–10181.
- 4 A. A. Joshi and C. L. Viswanathan, *Agents Med. Chem.*, 2006, 5, 105–122.
- 5 V. Nair, G. Chi, Q. Shu, J. Julander and D. F. Smee, *Bioorg. Med. Chem. Lett.*, 2009, **19**, 1425–1427.
- 6 S. I. Alqasoumi, A. M. Al-Taweel, A. M. Alafeefy, E. Noaman and M. M. Ghorab, *Eur. J. Med. Chem.*, 2010, 45, 738–744.
- 7 A. B. A. El-Gazzar, H. N. Hafez and G. A. M. Nawwar, *Eur. J. Med. Chem.*, 2009, **44**, 1427–1436.
- 8 V. Alagarsamy, Pharmazie, 2004, 59, 753-755.
- 9 V. Alagarsamy, R. Venkatesaperumal, S. Vijayakumar, T. Angayarkanni, P. Pounammal, S. Senthilganesh and S. Kandeeban, *Pharmazie*, 2002, 57, 306–307.
- 10 A. R. Moosavi-Zare, Z. Asgari, A. Zare, M. A. Zolfigol and M. Shekouhy, RSC Adv., 2014, 4, 60636.
- 11 A. R. Moosavi-Zare, M. A. Zolfigol, M. Zarei, A. Zare and V. Khakyzadeh, *J. Mol. Liq.*, 2015, **211**, 373.
- 12 Multicomponent Reactions, ed. J. Zhu and H. Bienayme, Wiley, Weinheim, 2005.
- 13 M. A. Zolfigol, A. Khazaei, A. R. Moosavi-Zare, A. Zare and V. Khakyzadeh, *Appl. Catal., A*, 2011, **400**, 70.
- 14 A. R. Moosavi-Zare and H. Afshar-Hezarkhani, Org. Prep. Proced. Int., 2020, 52, 410–421.
- A. R. Moosavi-Zare, M. A. Zolfigol, F. Derakhshan-Panah and S. Balalaie, *Mol. Catal.*, 2018, 449, 142–151.
- 16 A. R. Moosavi-Zare, H. Goudarziafshar and Z. Jalilian, *Appl. Organomet. Chem.*, 2019, **33**, e4584.
- 17 F. Jalili, M. Zarei, M. A. Zolfigol, S. Rostamnia and A. R. Moosavi-Zare, *Microporous Mesoporous Mater.*, 2020, 294, 109865.
- 18 A. Zare, M. Dianat and M. M. Eskandari, New J. Chem., 2020, 44, 4736–4743.
- 19 F. Osanlou, F. Nemati and S. Sabaqian, *Res. Chem. Intermed.*, 2017, **43**, 2159–2174.
- 20 I. M. Moghaddampour, F. Shirini and M. S. N. Langarudi, J. Mol. Struct., 2021, 1226, 129336.
- 21 O. G. Jolodar, F. Shirini and M. Seddighi, *Chin. J. Catal.*, 2017, **38**, 1245–1251.

- 22 A. M. Rad and M. Mokhtary, Int. Nano Lett., 2015, 5, 109-123.
- 23 F. Shirini, M. S. N. Langarudi, N. Daneshvar, N. Jamasbi and M. Irankhah-Khanghah, J. Mol. Struct., 2018, 1161, 366–382.
- 24 D.-Q. Shi, S.-N. Ni, F. Yang, J.-W. Shi, G.-L. Dou, X.-Y. Li, X.-S. Wang and S.-J. Ji, *J. Heterocycl. Chem.*, 2008, **45**, 693.
- 25 R. Schlögl, Angew. Chem. Int. Ed., 2015, 54, 3465-3520.
- 26 J. M. Thomas and W. J. Thomas, *Principles and practice of heterogeneous catalysis*, 2nd edn, 2014, Weinheim, Germany.
- 27 M. A. Zolfigol, V. Khakyzadeh, A. R. Moosavi-Zare,
 A. Rostami, A. Zare, N. Iranpoor, M. H. Beyzavi and
 R. Luque, *Green Chem.*, 2013, 15, 2132–2140.
- 28 A. Khazaei, A. R. Moosavi-Zare, H. Afshar-Hezarkhani and V. Khakyzadeh, RSC Adv., 2014, 4, 32142–32147.
- 29 A. Khazaei, F. Gholami, V. Khakyzadeh, A. R. Moosavi-Zare and J. Afsar, *RSC Adv.*, 2015, 5, 14305–14310.
- 30 M. Bagherzadeh, M. M. Haghdoost and A. Shahbazirad, J. Coord. Chem., 2012, 65, 591–601.
- 31 S. Saedi and J.-W. Rhim, *Food Packaging and Shelf Life*, 2020, 24, 100473.
- 32 A. R. Sardarian, M. Zangiabadi and I. D. Inaloo, *RSC Adv.*, 2016, **6**, 92057–92064.
- 33 A. R. Sardarian, I. D. Inaloo and M. Zangiabadi, New J. Chem., 2019, 43, 8557–8565.
- 34 M. T. H. Tarafder, K. B. Chew, K. A. Crouse, A. M. Ali, B. M. Yamin and H. K. Fun, *Polyhedron*, 2002, 21, 2683–2690.
- 35 H. A. Ali, M. D. Darawsheh and E. Rappocciolo, *Polyhedron*, 2013, **61**, 235–241.
- 36 S. A. da Silva, C. Q. F. Leite, F. R. Pavan, N. Masciocchi and A. Cuin, *Polyhedron*, 2014, **79**, 170–177.
- 37 A. R. Moosavi-Zare, H. Goudarziafshar and L. Ghaffari, *Appl.* Organomet. Chem., 2017, **31**, e3845.
- 38 A. R. Moosavi-Zare, H. Goudarziafshar and Z. Jalilian, *Appl. Organomet. Chem.*, 2019, **33**, e4584.
- 39 A. R. Moosavi-Zare, H. Goudarziafshar and K. Saki, *Appl. Organomet. Chem.*, 2018, **32**, e3968.
- 40 H. Goudarziafshar, A. R. Moosavi-Zare and J. Hasani, *Appl. Organomet. Chem.*, 2020, **34**, e5372.
- 41 A. R. Moosavi-Zare, H. Goudarziafshar and F. Nooraei, *Appl. Organomet. Chem.*, 2020, **34**, e5252.
- 42 A. R. Moosavi-Zare, H. Goudarziafshar, M. A. Delkhosh and Z. Jalilian, Org. Prep. Proced. Int., 2021, 53, 402–412.
- 43 A. R. Moosavi-Zare, H. Goudarziafshar and P. Fashi, *Res. Chem. Intermed.*, 2020, **46**, 5567–5582.
- 44 M. Jayendran, P. M. S. Begum and M. R. P. Kurup, *J. Mol. Struct.*, 2020, **1206**, 127682.
- 45 J. Xu, C. Ju, J. Sheng, F. Wang, Q. Zhang, G. Sun and M. Sun, Bull. Korean Chem. Soc., 2013, 34, 2408–2412.
- 46 G.-p. Lu and C. Cai, J. Heterocycl. Chem., 2014, 51, 1595–1602.